Hints and tips:
Related Special Reports
Related Topics
...In second place, with five promotions and demotions, is Hikma Pharmaceuticals....
...Index complier FTSE Russell confirmed the move on Wednesday afternoon, adding that technical products provider Diploma, Hikma Pharmaceuticals and Dechra Pharmaceuticals would also join the blue-chip index...
...That’d be bad news for Hikma Pharmaceuticals (27.2 per cent). What about board chairs and their deputies?...
...Initially, the framework will be used to assess the efforts of five companies: Cipla, Hikma, Sun Pharma, Teva and Viatris....
...Sainsbury’s holding up better than feared; Rolls-Royce maintains guidance but cautions about supply chain snarling; Howden’s is fine; Smith & Nephew beats; Harbour Energy raises; Trainline recovers; and Hikma...
...The other expected deletion, which will be confirmed on Wednesday based on prices at close of trading the day before, is Hikma Pharmaceuticals....
...endgame (University of Cambridge) — RNS watch is a challenge this morning because LSE’s site’s broken again: meaning the author has not yet read about Rolls-Royce H1s; Glencore H1s; a Next trading update; Hikma...
...We stated GSK’s Emma Walmsley was almost 30 basis points points a year behind Sigurdur Olafsson of Hikma, when it should be percentage points....
...Hikma posted a half-year operating profit of $326m, up 10 per cent, on revenue up 7 per cent to $1.2bn....
...Hikma Pharmaceuticals, a large dexamethasone manufacturer, said demand for the drug had risen “substantially” since the results of the Oxford trial became public on Tuesday....
...Shares in Vectura, whose clients include GlaxoSmithKline and Hikma Pharmaceuticals, closed up 14 per cent at 155p....
...Hikma Pharmaceuticals said in a trading update that 2021 “is off to a good start with performance in line with our expectations”....
...And Stifel just likes Hikma: Hikma continues to drive good organic growth across its three divisions....
...Generic drug maker Hikma said core operating profit grew 17 per cent to $566m in 2020....
...Jefferies cuts Hikma to “hold”. Valuation, mostly. HIK's >35% outperformance since pre-COVID leaves limited value in our view....
...Citigroup’s not keen on Hikma, the price gouging pharma....
...Stocks paring a portion of their through-the-crisis gains in recent weeks include Hikma Pharmaceuticals, medical products maker ConvaTec and Polymetal, the Russian gold miner....
...Pharma group Hikma has also joined that rare group of companies that has been able to hike its payout to shareholders, after operating profit rose 25 per cent in the first half of the year....
...Amarin heart drug: Shares of Hikma have outperformed SXDP by c.500bps, following the favourable Federal Court decision on generic Vascepa (September 3)....
...Offices belonging to Hikma and other political parties were attacked in some provincial cities....
...Hikma missed out on a FTSE 100 rally after Citigroup downgraded it to “neutral”. The drugmaker had a modest roster of product launches for 2019 and faced growing competition, said Citi....
...● Citigroup upgraded generic drugmaker Hikma Pharmaceuticals to “buy” from “neutral” with an £18.70 target price....
...Hikma Pharmaceuticals, aerospace engineer Meggitt and Russian gold miner Polymetal International are all set to added to the blue-chip index, FTSE said based on closing share prices from Friday....
...says others are not safe from entering the drop zone: “With markets looking volatile, last-minute changes ahead of the reshuffle deadline on 3 March could also put recent entrant Just Eat, Takeaway.com, Hikma...
...Siggi Olafsson, chief executive of Hikma, said: “The generic respiratory market is a key area of pipeline focus for Hikma . . ....
International Edition